APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Disease: Memory impairment ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. 17258906 2007
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE To investigate if increasing plasma apoA-I/HDL levels ameliorates AD-like memory deficits and amyloid-β (Aβ) deposition, we generated a line of triple transgenic (Tg) mice overexpressing mutant forms of amyloid-β precursor protein (APP) and presenilin 1 (PS1) as well as human apoA-I (AI). 20847045 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE FGF2 treatment attenuated spatial memory deficits, reduced amyloid-β (Aβ) and tau pathologies, decreased inducible nitric oxide synthase expression, and increased the number of astrocytes in the dentate gyrus in APP 23 mice compared with the vehicle-treated controls. 25457554 2015
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE These findings show a selective upregulation of astroglial B1R in the APP mouse brain, and the capacity of the B1R antagonist to abrogate amyloidosis, cerebrovascular and memory deficits. 23642031 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Transgenic mice carrying AD-causing mutations in APP develop spontaneous age-related beta-amyloid (A beta) deposition and memory impairment. 9052714 1997
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE In two unrelated UK families with APP 717 val-ile mutations there was early prominent memory impairment with dyscalculia proceeding to generalized cognitive impairment with a lack of insight. 8239283 1993
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE In mice carrying the APP(Swe/Ind) mutation (J20 mice), Reelin overexpression delays amyloid plaque formation and rescues the recognition memory deficits. 24599114 2014
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Chronic treatments with two γ-secretase modulators, ibuprofen and CHF5074, disclosed higher activity of CHF5074 in ameliorating brain plaque deposition and spatial memory deficits in transgenic mice expressing human amyloid precursor protein (hAPP) with Swedish and London mutations (APP(SL) mice). 21181298 2011
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE We previously showed that mice over-expressing a human mutated form of APP (APP(V717F)) display age-dependent recognition memory deficits associated with the progression of amyloid deposition. 10718322 2000
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE The Tg-APP (Sw, V717F)/B6 mice at 11-14 months displayed decreased motor coordination, learning and memory deficits, and severely increased anxiety. 15114629 2004
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Hypoxia treatment markedly increased Abeta deposition and neuritic plaque formation and potentiated the memory deficit in Swedish mutant APP transgenic mice. 17121991 2006
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE In this report, we found that a PSEN1 mutation (S169del) altered APP processing and Aβ generation, and promoted neuritic plaque formation as well as learning and memory deficits in AD model mice. 29915376 2020
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE After three months treatment with CBZ in the APP(swe)/PS1(deltaE9) mice, we demonstrated that the spatial learning and memory deficits in these mice are significantly alleviated. 23305067 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Tg19959 mice carry human APP with two mutations and develop amyloid plaques and memory impairment starting at 3-4 months of age. 19914323 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE To investigate whether GSK-3 inhibition can reduce amyloid and tau pathologies, neuronal cell death and memory deficits in vivo, double transgenic mice coexpressing human mutant APP and tau were treated with a novel non-ATP competitive GSK-3beta inhibitor, NP12. 19523516 2009
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Mutant Tg2576 mice which possess the human "Swedish" APP mutation have been shown to demonstrate both Abeta plaque pathology and memory deficits in behavioral tasks. 19944081 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE A recently described mouse line, Tg(HuAPP695.K670N/M671L)2576, expressing human amyloid precursor protein with a familial AD gene mutation, age-related amyloid deposits, and memory deficits, was found to develop a significant microglial response using Griffonia simplicifolia lectin or phosphotyrosine probe to identify microglia Both Griffonia simplicifolia lectin and phosphotyrosine staining showed increased numbers of intensely labeled, often enlarged microglia clustered in and around plaques, consistent with microglial activation related to beta-amyloid formation. 9422548 1998
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Transgenic mice that overexpress the Swedish mutation of human amyloid precursor protein (hAPPswe; Tg2576) show age-dependent memory deficits in hippocampus-dependent learning tasks. 12359834 2002
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. 30050407 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Importantly, APP/PS1/δ<sup>D910A</sup> mice exhibited no spatial learning or memory deficits. 31363064 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Increased ILK expression of dentate gyrus (DG) rescued the hippocampus-dependent neurogenesis and memory deficits in APP/PS1 mice. 29787769 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Increase in presenilin 1 (PS1) levels in senescence-accelerated mice (SAMP8) may indirectly impair memory by affecting amyloid precursor protein (APP) processing. 19181896 2009
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we confirmed that four weeks' treatment of exendin-4 could rescue memory deficits and neuropathological changes in APP/PS1 mice. 29223528 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE First, silibinin and silymarin administration could alleviate memory deficits and reduce the amyloid plaque burden in the brain of APP/PS1 mice in comparison with controls. 31236617 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Restraint/isolation stress induced significant depressive-like behaviors in APP/PS1 mice at 4 months of age and memory impairment at 10 months of age, while 6 months of icariin administration relieved the memory damage. 31001073 2019